公开(公告)号：EP3328411A1

公开(公告)日：2018-06-06

申请号：EP16831292.4

申请日：2016-07-27

Applicant: Layerbio, Inc.

Inventor： WHITE, Aleksandr ,  MANDELL, Kenneth

IPC: A61K38/14

CPC classification number: A61K9/0048 ,  A61K31/165 ,  A61K31/5575 ,  A61K31/573 ,  A61K31/7036 ,  A61K31/7048 ,  A61K47/645 ,  C08G69/10 ,  C08G69/48

Abstract: A polymer-drug conjugate includes a crosslinked polymer network comprising a biocompatible polymer and a multivalent covalent crosslinker, wherein the multivalent crosslinker comprises an active ingredient precursor covalently bonded through two or more bonds to the biocompatible polymer, and wherein the covalent bond is a hydrolysable bond. The drug can be for treatment of glaucoma and the free drug is biologically active and selected to lower eye pressure.

公开(公告)号：EP3328370A1

公开(公告)日：2018-06-06

申请号：EP16750683.1

申请日：2016-07-28

Applicant: Université de Bordeaux ,  Centre Hospitalier Universitaire de Bordeaux

Inventor： LAFITTE, Stéphane

IPC: A61K31/165 ,  A61P9/02 ,  A61K31/137

CPC classification number: A61K31/165 ,  A61K9/0029 ,  A61K9/0053 ,  A61K9/08 ,  A61K31/137 ,  A61K31/138 ,  A61K2300/00 ,  A61P9/02

Abstract: The present invention refers to a substance for use in the treatment of obstructive cardiopathy, in particular to a substance selected among midodrine, a pharmaceutical salt, and the active metabolite thereof, for use in the treatment of obstructive cardiopathy.

公开(公告)号：EP3322438A1

公开(公告)日：2018-05-23

申请号：EP16738165.6

申请日：2016-07-12

Applicant: Dompé farmaceutici S.p.A.

Inventor： ALLEGRETTI, Marcello ,  ARAMINI, Andrea ,  CESTA, Maria, Candida ,  BIANCHINI, Gianluca ,  BRANDOLINI, Laura ,  ANGELICO, Patrizia

IPC: A61K39/00 ,  A61K45/06 ,  A61K31/165 ,  A61K31/381 ,  A61K31/407 ,  A61K31/426 ,  A61K31/675 ,  A61K31/704 ,  A61P13/10

CPC classification number: A61K31/426 ,  A61K31/165 ,  A61K31/381 ,  A61K31/407 ,  A61K31/664 ,  A61K31/675 ,  A61K31/704 ,  A61K45/06 ,  A61K2300/00 ,  A61P13/10

Abstract: The present invention relates to IL-8 inhibitor compounds, preferably dual CXCR1/CXCR2 receptor inhibitors, useful in the treatment and/or prevention of interstitial cystitis / painful bladder syndrome (IC/PBS) and/or over active bladder (OAB), also including IC/PBS and/or OAB induced by anticancer therapy. Methods of treatment and/or prevention, combinations and kits comprising said IL-8 inhibitors are also covered therein.

公开(公告)号：EP3316886A1

公开(公告)日：2018-05-09

申请号：EP16739596.1

申请日：2016-06-30

Applicant: Svensson, Camilla ,  Klareskog, Lars ,  Malmström, Vivianne ,  Catrina, Anca

Inventor： Svensson, Camilla ,  Klareskog, Lars ,  Malmström, Vivianne ,  Catrina, Anca

IPC: A61K31/496 ,  A61K31/341 ,  A61K31/165 ,  A61P29/00

CPC classification number: A61K31/496 ,  A61K31/165 ,  A61K31/341

Abstract: Pain associated with a contribution of IL-8 and osteoclasts in a subjectis prevented, treated and/or alleviated by the administration of an effective amount of a compound capable of inhibiting or blocking the action of interleukin8 (IL-8 ). Methods and compounds for this use are disclosed, as well as a diagnostic method and kit.

公开(公告)号：EP3316857A1

公开(公告)日：2018-05-09

申请号：EP16733595.9

申请日：2016-06-30

Applicant: Sequessome Technology Holdings Limited

Inventor： GARRAWAY, Richard Wolf ,  HENRY, William

IPC: A61K9/00 ,  A61K8/43 ,  A61K9/10 ,  A61K31/155 ,  A61P17/00 ,  A61K47/26 ,  A61K47/24 ,  A61K9/127

CPC classification number: A61K9/0014 ,  A61K8/43 ,  A61K9/10 ,  A61K9/127 ,  A61K9/1272 ,  A61K31/155 ,  A61K31/165 ,  A61K31/355 ,  A61K31/522 ,  A61K31/60 ,  A61K31/618 ,  A61K31/7008 ,  A61K31/737 ,  A61K47/24 ,  A61K47/26 ,  A61K2300/00

Abstract: The present invention relates to compositions comprising a colloidal dispersion and an Agent of Interest (“AOI”), wherein the colloidal dispersion comprises deformable colloidal particles and wherein the AOI is not associated with the deformable colloidal particles. The present invention also provides kits and transdermal drug release devices comprising the compositions of the present invention, and the use of these compositions in medicine, skin care and cosmetics.

公开(公告)号：EP2481429B1

公开(公告)日：2018-05-09

申请号：EP12160565.3

申请日：2008-03-27

Applicant: Incanthera Limited

Inventor： Gill, Jason ,  Loadman, Paul ,  Falconer, Robert ,  Patterson, Laurence ,  Atkinson, Jennifer ,  Bibby, Michael

IPC: A61K47/65 ,  C07K7/06 ,  A61P35/00 ,  A61P29/02 ,  A61P9/08

CPC classification number: A61K47/64 ,  A61K31/165 ,  A61K31/704 ,  A61K47/55 ,  A61K47/60 ,  A61K47/65 ,  C07K7/06

Abstract: The present invention relates to compounds, and pharmaceutically acceptable salts thereof, comprising a vascular disrupting agent (VDA) associated and a MMP proteolytic cleavage site. The compounds are useful in the treatment of cancer.

公开(公告)号：EP2437732B1

公开(公告)日：2018-05-09

申请号：EP10784223.9

申请日：2010-06-07

Applicant: VeroScience LLC

Inventor： CINCOTTA, Anthony, H.

IPC: A61K31/48 ,  A61K38/36 ,  A61K45/06 ,  A61K9/22 ,  A61P3/10

CPC classification number: A61K31/48 ,  A61K31/00 ,  A61K31/165 ,  A61K31/195 ,  A61K31/4453 ,  A61K31/4985 ,  A61K38/22 ,  A61K38/2278 ,  A61K38/26 ,  A61K38/28 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention is directed to a method of treating a metabolic disorder or key elements of a metabolic disorder such method comprising the use of an agent(s) that increases central dopaminergic activity plus a first-phase insulin secretagouge.

公开(公告)号：EP3157512B1

公开(公告)日：2018-04-25

申请号：EP15732887.3

申请日：2015-06-17

Applicant: GW Pharma Limited

Inventor： GUY, Geoffrey ,  WRIGHT, Stephen ,  MEAD, Alice ,  CHEETHAM, Emma ,  DEVINSKY, Orrin ,  SCHILLER, Dominic

IPC: A61K31/05 ,  A61K31/195 ,  A61K31/20 ,  A61K31/27 ,  A61K31/352 ,  A61K31/4015 ,  A61K31/4166 ,  A61K31/423 ,  A61K31/496 ,  A61K31/53 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/5517 ,  A61K31/7048 ,  A61P25/10

CPC classification number: A61K31/05 ,  A61K9/0053 ,  A61K9/08 ,  A61K31/165 ,  A61K31/19 ,  A61K31/195 ,  A61K31/197 ,  A61K31/20 ,  A61K31/27 ,  A61K31/35 ,  A61K31/352 ,  A61K31/36 ,  A61K31/4015 ,  A61K31/4166 ,  A61K31/423 ,  A61K31/444 ,  A61K31/496 ,  A61K31/515 ,  A61K31/53 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/5517 ,  A61K31/7048 ,  A61K36/185 ,  A61K45/06 ,  A61K47/10 ,  A61K47/26 ,  A61K47/44 ,  A61K2300/00

Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

公开(公告)号：EP3157511B1

公开(公告)日：2018-04-25

申请号：EP15732886.5

申请日：2015-06-17

Applicant: GW Pharma Limited

Inventor： GUY, Geoffrey ,  WRIGHT, Stephen ,  MEAD, Alice ,  JOSHI, Charuta ,  WILFONG, Angus

IPC: A61K31/05 ,  A61K31/195 ,  A61K31/20 ,  A61K31/27 ,  A61K31/352 ,  A61K31/4015 ,  A61K31/4166 ,  A61K31/423 ,  A61K31/496 ,  A61K31/53 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/5517 ,  A61K31/7048 ,  A61P25/10

CPC classification number: A61K31/05 ,  A61K9/0053 ,  A61K9/08 ,  A61K31/165 ,  A61K31/19 ,  A61K31/195 ,  A61K31/197 ,  A61K31/20 ,  A61K31/27 ,  A61K31/35 ,  A61K31/352 ,  A61K31/36 ,  A61K31/4015 ,  A61K31/4166 ,  A61K31/423 ,  A61K31/444 ,  A61K31/496 ,  A61K31/515 ,  A61K31/53 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/5517 ,  A61K31/7048 ,  A61K36/185 ,  A61K45/06 ,  A61K47/10 ,  A61K47/26 ,  A61K47/44 ,  A61K2300/00

Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

公开(公告)号：EP3288518A1

公开(公告)日：2018-03-07

申请号：EP16789381.7

申请日：2016-05-02

Applicant: Sun Pharmaceutical Industries Limited

Inventor： BHARGAVA, Rahul ,  MITTAL, Bhupesh Kumar ,  RAMARAJU, Kalaiselvan ,  KUMAR, Ashish

IPC: A61J1/14 ,  A61K9/14 ,  B65D25/08

CPC classification number: A61J1/2093 ,  A61J1/1418 ,  A61J1/18 ,  A61J1/2006 ,  A61J1/2027 ,  A61K9/0095 ,  A61K9/10 ,  A61K9/145 ,  A61K9/5015 ,  A61K9/5042 ,  A61K9/5047 ,  A61K9/5084 ,  A61K9/5089 ,  A61K31/155 ,  A61K31/165 ,  A61K31/43 ,  A61K31/4439 ,  A61K31/522 ,  A61K47/12 ,  A61K47/14 ,  A61K47/26 ,  A61K47/36 ,  A61K47/38 ,  B65D51/2835 ,  B65D81/3211 ,  B65D2101/0038 ,  B65D2101/0076

Abstract: The present invention relates to a dual-chamber pack comprising a first chamber prefilled with a suspension base and a second chamber prefilled with a powder for suspension comprising an active ingredient, wherein upon activation of the dual-chamber pack, the contents of both the chambers are mixed to form an extended release suspension composition which is characterized by having no substantial change in the in-vitro dissolution release profile of the active ingredient upon storage for at least seven days.